In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

Safety issues that led to the withdrawals of the cannabinoid receptor antagonist Acomplia (rimonabant) and, before that, appetite suppressant Redux (dexfenfluramine), mean that novel products are ...

1, 1; 2008). Two major drugs that analysts had previously expected to be launched in 2007, Acomplia (rimonabant; Sanofi–Aventis) for obesity and Galvus (vildagliptin; Novartis) for type 2 ...

Sanofi's Acomplia, which never won U.S. approval, was withdrawn in Europe in 2008 after being linked to suicidal thoughts. The weight-loss drug Contrave carries a black box warning about suicidal ...

Shares of the Paris-based drug giant have fallen about 9% since July 2006 because of concerns about generic competition and delays in the launch of its anti-obesity product, Acomplia. But a rich ...